Navigation Links
Robert Storey Joins VIC Technology Venture Development as Executive in Residence
Date:2/14/2013

Fayetteville, AR (PRWEB) February 14, 2013

VIC Technology Venture Development (VIC) is pleased to announce that Robert (Bob) Storey has joined the company as Executive in Residence. Mr. Storey will assist in the assessment and creation of new ventures, then serve as interim CEO for newly formed portfolio companies, especially those focusing on medical devices and engineered materials. In managing these companies, he will provide expertise in business development, marketing, and corporate strategic planning. As CEO for VIC’s startup companies, Mr. Storey will not only manage their operations but will also oversee the development and execution of key commercial milestones, such as resource plans, funding, and recruitment of permanent CEOs and management teams.

“We are indeed fortunate to add Bob’s considerable talents to our development team,” said Calvin Goforth, President and Founder of VIC. “His energy and contributions to the efforts of our young technology companies have been immediately apparent.”

Mr. Storey is no newcomer to the art of new business development. He has over 30 years of experience in this field, especially with startups in regulated industries. Most recently as Executive-in-Residence at Johns Hopkins University, he has helped commercialize technology developed at the University Medical School and the Whiting School of Engineering.

After earning degrees in chemical engineering and chemistry at the University of Arkansas, Mr. Storey took a job with Exxon Corporation. His path led from the Technology Center to Exxon’s American Headquarters in Houston, where he worked in business planning and mergers and acquisitions. He advised Exxon’s Corporate Controller, the Sales and Marketing division, and the leadership of Exxon’s international joint venture with Mitsubishi Petrochemical.

In 1994, Mr. Storey left Exxon to become Vice President and General Manager of a privately held engineering company in Maryland. He led the company through a successful sale to Clariant Corporation of Switzerland, where he served as Vice President of Clariant’s Performance Plastics division.

In 1999, Mr. Storey led Vapotherm, a Maryland company, as President and CEO. The firm, which specialized in non-invasive respiratory devices, received the U.S Commerce Department’s Export Achievement Award, the Maryland World Trade Center International Leadership Award, and Deloitte’s Technology Fast 500 award, four times.
Mr. Storey currently serves on the Dean’s Advisory Council for the University of Arkansas's School of Engineering and is President Emeritus of the Arkansas Academy of Chemical Engineers. He is a Board Member and past President of the Maryland Upper Shore Manufacturing & Business Council, and served on Chesapeake College’s Presidential Search Committee.

About VIC:

VIC Technology Venture Development, LLC is a technology venture development firm that creates innovative new companies with world changing science and engineering based technologies. VIC carefully selects, then licenses technologies from universities and research institutions, then partners technology entrepreneurs with business experts, technology experts and seed stage investors. VIC provides its portfolio companies with senior management expertise, intimate knowledge of technology startups, and proven processes to execute business strategies. Its team members bring extensive experience across legal, financial, operations, marketing, capital acquisition, and technology management areas. VIC experts help their portfolio companies meet management and business planning goals by providing appropriate support at each stage in their development, only as it is needed.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10432667.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Pittcon Announces 2013 Award Recipients; New Award, Robert Boyle Prize for Analytical Science, Added to Technical Program
2. Robert Haynes To Lead Licensing As VR Laboratories Senior Vice President Product Introduction And Licensing
3. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
4. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
5. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
6. Robert Farrell Joins Bionovos Board of Directors
7. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
8. Michael Berman Joins InspireMD Board
9. Rudy Mazzocchi Joins the Greatbatch Board of Directors as he Continues to Expand his Presence in the Med-tech Industry
10. Diabetes Research Institute Foundation’s (DRIF) CEO Joins Healthcare Holdings Group, Inc. Board of Directors
11. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg based clinical stage biotechnology ... patients. LHON is a rare devastating genetic disease that leads to a sudden and ... group of 20 patients carrying 11778, 14484 and 3460 mutations and having experienced the ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra ... controllers based on capillary thermal mass flow technology provide exponentially more accurate mass ... Over 80% of all industrial processes—such as those involving chemical reactions, combustion, ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ex-FDA official ... trials comes to Tampa, San Francisco and Boston in 2017. The 2016 ... organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix Inc., Cell ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):